An international committee of experts will release an interim report in early 2025 outlining criteria for diagnosing ...

After years of rising obesity rates in the US, the numbers dipped slightly during 2023, though experts disagree about the ...

Innovation, artificial intelligence, drug costs and shortages, private equity interests, and more left their mark in ...

The Food and Drug Administration (FDA) announced the approval of the weight loss drug Zepbound, generically known as ...

GLP-1 receptor agonists, which can cost around $1,300 a month, have caused an increase in premiums that “affect all members, ...

The effects that a pause may have on your body may depend on why you're taking the medication in the first place.

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...

Novo Nordisk has an opportunity to expand indications on its weight loss drugs. Check out on what could be next for NVO stock ...

One lawmaker said the CT Department of Social Services told him the agency wasn’t paying for FDA-approved drugs because of ...

An international committee of experts will release an interim report in early 2025 outlining criteria for diagnosing ...

The decision will largely prevent compounding pharmacies from making and selling compounded versions of the drug in the next ...

Novo Nordisk ADR (NYSE: NVO) currently trades at $89 per share, nearly 40% below its peak level of over $145 seen in June of ...